HUM-MOLGEN events: Research Based Oncology

HUM-MOLGEN -> Events -> Meetings and Conferences

July 10, 2001

SMi Conferences, London, England
2001/10/17

Wednesday 17th October 2001

8.30 Registration & Coffee

9.00 Chairman's Opening Remarks
CONFIRMED Dr Lars Breimer, Clinical Science Leader, Global Drug Development, Roche

NEW TARGETS AND APPROACHES

DEVELOPMENTS IN RESEARCH BASED ONCOLOGY
9.10 From biological function to drug molecular design
 Targeting cancerous cells effectively
 Recent developments in multidrug treatments
 Human multidrug resistance- associated protein (MRP)
 P-glycoproteins and other ABC proteins
 Is transport mechanism-based drug molecular design possible?
CONFIRMED Dr Toshihisa Ishikawa, Tokyo Institute of Technology,

CHEMOPREVENTION
9.40 The role of cyclooxygenase-2 (COX-2) inhibitors
 Colon cancer: familial and sporadic
 COX-2 Inhibitors and cancer prevention
 Vioxx:chemoprevention of colon cancer
 Market size and demographics
 Future prospects for COX-2 inhibitors in other cancers
CONFIRMED Dr Jillian Evans, Director, Pharmacology, Merck Research Laboratories

NEW WEAPONS IN THE CANCER WAR
10.20 Cell Cycle Inhibition as a novel therapeutic approach
 Molecular biology of the cell cycle
 Dysregulation of cell growth in cancer
 Impact of cell surface signalling on the cell cycle
 Check-points and components as novel targets
 Potential of the new classes of drugs in clinical trials
CONFIRMED Dr Lars Breimer, Clinical Science Leader, Global Drug Development, Roche

11.00 Morning Coffee

ENZYMES AND SIGNAL TRANSDUCTION

PROTEIN KINASE INHIBITORS
11.20 New modalities in cancer treatment
 Cyclin-dependent protein kinases, EGF-R/VEGFR and Abl kinases
 Protein phosphorylation
 Antiproliferative and antiangiogenic
 Growth factors and receptor tyrosine kinases
 Animal models
 Control of multi-genic diseases: applications in cancer
CONFIRMED Dr Doriano Fabbro, Head, In vitro Lead Profiling, Oncology Research Novartis

ENZYME INHIBITORS
12.00 Case study: 6193965
 C-Jun N-terminal kinase (JNK) pathway
 Tumor necrosis factor – alpha (TNF-alpha)
 Mechanism: supression of cytokines, growth factors and enzymes
 Oral delivery
 Control of multi-genic diseases : applications in cancer
CONFIRMED Dr Robert Hugin, Senior Vice President & Chief Financial Officer, Celgene

12.40 Lunch
AVAILABLE FOR SPONSORSHIP
For further information of how to take up this targeted marketing opportunity please contact Naomi Koningen.
Email: nkoningen@smi-online.co.uk Tel: +44 (0) 20 7827 6054 Fax: +44 (0) 20 7827 6055

SIGNAL TRANSDUCTION AND PROTEIN KINASE INHIBITORS
2.00 Case study
 Blocking components of PI3K signalling pathway
 Inhibiting ILK and PKB mediated signal transduction
 Dysregulation of ILK and PKB in human tumors
 In vivo efficacy in xenograft models with ILK and PKB inhibitors
CONFIRMED Dr Jasbinder Sanghera, Chief Scientific Officer, Kinetekpharm

SELECTIVE APOPTOSIS: cGMP PHOSPHODIESTERASE INHIBITION
2.40 Targets for Cytostatic and Cytotoxic Drug Development
 The role of cGMP and cGMP phosphodiesterases (cGMP PDEs) in
 apoptosis
 proliferation
 angiogenesis
 Pro-apoptotic cGMP PDE inhibitors - A paradigm for new drug candidate discovery
 Preclinical and clinical findings with modulators of the cGMP – protein kinase G pathway
 Challenges in the clinical development of cytostatic agents compared to cytotoxic agents
CONFIRMED Dr Rifat Pamukcu, Co-Founder, Chief Scientific Officer, Executive Vice President, Research & Development, Cell Pathways

3.20 Afternoon Tea
AVAILABLE FOR SPONSORSHIP
For further information of how to take up this targeted marketing opportunity please contact Naomi Koningen.
Email: nkoningen@smi-online.co.uk Tel: +44 (0) 20 7827 6054 Fax: +44 (0) 20 7827 6055

IMMUNOLOGICAL APPROACHES

RECEPTOR BINDING
3.40 Alphavbeta3, a pivotal integrin
 Human malignant melanoma therapies
 The vitronectin receptor – survival signals
 Role in melanoma progression and in tumor angiogenesis
 Antagonists: as anti tumour drugs in vivo
 hMAb’s
 17E6
 Cyclic RGD
 Therapeutic potential
CONFIRMED Dr Francesc Mitjans, Project Leader, Merck Farma y Quimica

AGENT (ANTIBODY-GUIDED ENZYME NITRILE THERAPY)
4.20 Targeted cyanogenesis in tumours
 Recent advanced in antibody engineering
 Natural cyanogenesis
 Targeted cyanogenesis
 Recombinant production of fusion proteins
 In vitro characterisation
 Future developments
CONFIRMED Dr Mahendra Deonarain, Lecturer, Imperial College & Consultant, Antisoma, Imperial College University & Antisoma

5.00 Chairman’s Closing Remarks and Close of Day One

Thursday 17th October 2001

8.30 Re-registration and Coffee

9.00 Chairman's Opening Remarks
CONFIRMED Dr. John L.Herrmann, Project leader, Oncology program, CuraGen

IMMUNOTHERAPY
9.10 Case study: Murine leukaemia and lymphoma
 Soluble B7 immunoglobulin
 Tumour kinetics
 Autologous tumour associated antigens
 Major mechanisms
 Murine models
 T cell dependant responses
 Tumour specific immunity
 Safety profile
CONFIRMED Dr Kiri Dunussi- Joannopoulos, Principal Scientist, Genetics Institute Wyeth-Ayerst

NEW APPROACHES IN IMMUNOLOGY
9.40 Does the immune system really discriminate between self and non-self?
 What turns an immune response on & off?
 Do we need adjuvants?
 Why do mothers not reject their fetuses?
 Why are transplants rejected while tumors are not?
CONFIRMED Dr Polly Matzinger, Section Head, T Cell Tolerance and Memory Section, National Institute of Allergy and Infectious Diseases, National Institute of Health

IMMUNOTHERAPY OF CANCER
10.20 Using antigens engineered to be optimally processed by dendritic cells
 Antigen presenting cells as vehicles
 Pre clinical studies
 Genetically engineered antigens for optimal processing by dendritic cells
 Clinical experience in prostate cancer, multiple myeloma and breast cancer
CONFIRMED Dr David Urdal, President, Chief Scientific Officer, Dendreon

11.00 Morning Coffee

GENE TECHNOLOGY UPDATE

ANTI-CANCER TARGET DISCOVERY
11.20 Unbiased and systematic genomics –based approaches
 A case for being unbiased
 Open Architecture Technologies for the dissection of the cancer genome
 Scanning the genome for new targets
 Attacking the pharmaceutically tractable genome
 Data integration to accelerate target discovery
 Pathway mapping to de-orphanize druggable targets
 Triaging pre-clinical candidates
CONFIRMED Dr. John L.Herrmann, Project leader, oncology program, CuraGen

CANCER: THE DISEASE OF THE GENOME
12.00 Integration of Genomic Technologies in Oncology Target Discovery and Drug Development.
 The new era of oncology
 The new investigative arsenal
 genome-based information technologies
 genomics-related experimental technologies
 Deciphering the bio-molecular characteristics of proliferative diseases.
 Understanding the mechanisms and molecular characteristics of different cancers
 New opportunities for target discovery and improvements in oncology drug discovery
 Fulfilment of genomic technologies promise to improve the diagnosis and treatment of cancer.
CONFIRMED Dr Mark Rolfe, Director, Molecular & Cellular Oncology Department, Millennium Pharmaceuticals

12.40 Lunch
AVAILABLE FOR SPONSORSHIP
For further information of how to take up this targeted marketing opportunity please contact Naomi Koningen.
Email: nkoningen@smi-online.co.uk Tel: +44 (0) 20 7827 6054 Fax: +44 (0) 20 7827 6055

BRINGING THE DREAM ONE STEP CLOSER TO REALITY
1.40 Adenoviral and AAV Vectors for Anti-Angiogenesis Gene Therapy
 AV, AAV and lentiviral vectors for anti-angiogenic gene therapy
 p27-p16 gene therapy
 angiostatin/endostatin gene therapy
 modelling anti-angiogenic gene therapy
CONFIRMED Dr James McArthur, Principal Scientist & Senior Director of Preclinical Biology and Immunology, Cell Genesys

ANTISENSE OLIGONUCLEOTIDES
2.20 Exploiting the differences between malignant and normal cells
 Anti-sense technology
 Blocking growth and cell cycle related genes
 Pre – clinical studies
 Clinical trials
 The future of antisense technology
CONFIRMED Dr Jim Wright, President, Lorus Therapeutics

ANTI-ANGIOGENISIS APPROACHES

ANTI – ANGIOGENIC STRATEGIES FOR CANCER THERAPY
3.00 Current Research Initiatives at EntreMed
 Overview of anti-angiogenic strategies
 Proteins and small molecules as anti-angiogenic agents
 Advances in vaccine research
 Ongoing preclinical research
 Clinical research update
CONFIRMED Dr Donald Bottaro, Director, Department, Cell & Molecular Biology, EntreMed

3.40 Afternoon Tea
AVAILABLE FOR SPONSORSHIP
For further information of how to take up this targeted marketing opportunity please contact Naomi Koningen.
Email: nkoningen@smi-online.co.uk Tel: +44 (0) 20 7827 6054 Fax: +44 (0) 20 7827 6055

MONOCLONAL ANTIBODIES TARGETING VEGF
4.00 Basic Biology and Clinical Implications
 Recent advances in therapeutic MAb's in oncology
 Data update: neutralizing antibody against VEGF
 Development: anti-VEGF and bone growth
 Tumor models: anti-VEGF and tumor growth and metastasis
 Update on the phase II and III clinical data
 How does VEGF regulate hematopoiesis?
CONFIRMED Dr Hanspeter Gerber, Scientist, Genentech

ANTI-ANGIOGENESIS AND ANTI-CANCER STRATEGIES
4.30 Targeting the VEGF receptors KDR and flt1
 KDR antibody phase 1 study
 KDR antibody efficacy in a leukemia model
 Anticancer therapeutic potential of VEGFR1 (flt1)
 Anti-angiogenic and anti-cancer activity of flt1 antibody
 VEGF receptor antibodies in model of atherosclerosis.
CONFIRMED Dr Peter Bohlen, Senior Vice President, Research ImClone Systems

5.00 Chairman’s Closing Remarks and Close of Day

Organized by:

SARAH SANDS

Invited Speakers:

Dr Lars Breimer, Clinical Science Leader, Global Drug Development, Roche
Dr Jillian Evans, Director, Pharmacology, Merck Research Laboratories
Dr Hanspeter Gerber, Scientist, Genentech
Dr Polly Matzinger, Section Head, T Cell Tolerance and Memory Section, National Institute of Allergy and Infectious Diseases, National Institute of Health
Dr Kiri Dunussi- Joannopoulos, Principal Scientist, Genetics Institute Wyeth-Ayerst
Dr Mark Rolfe, Director, Molecular & Cellular Oncology Department, Millennium Pharmaceuticals
Dr Doriano Fabbro, Head, In vitro Lead Profiling, Oncology Research Novartis
Dr Francesc Mitjans, Project Leader, Merck Farma y Quimica
Dr Rifat Pamukcu, Co-Founder, Chief Scientific Officer, Executive Vice President, Research & Development, Cell Pathways
Dr Peter Bohlen, Senior Vice President, Research ImClone Systems
Dr James McArthur, Principal Scientist & Senior Director of Preclinical Biology and Immunology, Cell Genesys
Dr Robert Hugin, Senior Vice President & Chief Financial Officer, Celgene
Dr Jasbinder Sanghera, Chief Scientific Officer, Kinetekpharm
Dr Toshihisa Ishikawa, Tokyo Institute of Technology
Dr Mahendra Deonarain, Lecturer, Imperial College & Consultant, Antisoma, Imperial College University & Antisoma
Dr Jim Wright, President, Lorus Therapeutics
Dr David Urdal, President, Chief Scientific Officer, Dendreon
Dr. John L.Herrmann, Project leader, oncology program, CuraGen
Dr Donald Bottaro, Director, Department, Cell & Molecular Biology, EntreMed

Deadline for Abstracts:

N?A

Registration:

Jkennedy@smi-online.co.uk

E-mail:

ssands@smi-online.co.uk

Posted by:

Sarah Sands

Host:

213.38.112.46